• Bsa I (RNase-free): DNA Cleavage Workflow

  2026-09-13

  Bsa I (RNase-free), SKU K1095, provides sequence-directed DNA cleavage for gene cloning, recombinant DNA workflows, and other molecular biology research applications where RNA integrity must be protected. It is for controlled research use only and should not be used for diagnostic, clinical, or medical procedures.

• Cell Senescence β-Galactosidase Staining Kit

  2026-09-12

  This scenario-based guide explains how Cell Senescence β-Galactosidase Staining Kit K2185 supports reproducible senescent cell detection in cultured cells and frozen tissue sections. It covers assay design, polystyrene compatibility, protocol controls, interpretation limits, and practical vendor-selection criteria for cell aging research.

• METTL14, DHRS4-AS1, and UC Inflammation

  2026-09-11

  A 2024 study identifies METTL14-dependent m6A modification of the lncRNA DHRS4-AS1 as a protective mechanism in ulcerative colitis. Its cell and mouse experiments connect this RNA-regulatory event to the miR-206/A3AR axis, NF-κB activation, apoptosis, and inflammatory tissue damage.

• Amikacin Sulfate: Assay Workflows and Optimization

  2026-09-11

  Amikacin Sulfate supports more than routine antimicrobial testing: it enables dose-response studies, intracellular infection models, and translational work on granuloma-targeted delivery. This guide connects quantitative CFU workflows with a functional-selection concept from Cas9 inhibitor discovery, while separating reported evidence from practical assay recommendations.

• Amikacin Sulfate: NTM Research Evidence

  2026-09-10

  Amikacin Sulfate is an aminoglycoside research compound with reported bactericidal activity against Mycobacterium avium and Staphylococcus aureus. Preclinical evidence supports targeted drug delivery of amikacin into M. avium granulomas, while assay-specific exposure, ototoxicity, nephrotoxicity, and model limitations remain important constraints.

• eIF4F, AKT1, and EZH2 in BRAF-Mutant Melanoma

  2026-09-10

  The reference study identifies coordinated ERK1/2–EZH2 and AKT1–eIF4E signaling as adaptive resistance mechanisms activated by eIF4F inhibition in BRAFV600E melanoma. Its combination experiments show that simultaneous targeting of eIF4F, EZH2, and AKT1 can improve suppression of sensitive and resistant melanoma models and restore response to BRAF inhibition.

• Streptavidin-FITC for LNP Tracking and Assays

  2026-09-09

  Streptavidin-FITC provides a practical fluorescent route for detecting biotinylated antibodies, nucleic acids, and nanoparticle-associated biomolecules across imaging and flow workflows. This guide connects assay design with recent LNP biology, showing how to distinguish particle localization from functional nucleic acid delivery.

• Macrophage EP4, CD36, and Atherosclerosis

  2026-09-09

  The reference study identifies macrophage EP4 loss as a driver of atherosclerosis progression, linking increased CD36 expression with foam cell formation and M1 polarization. Its combination of a myeloid-specific knockout model, oxLDL-stimulated macrophages, transcriptomics, proteomics, qPCR, and Western blotting provides a mechanistic framework for interpreting how lipid uptake and inflammation interact in plaques.

• Direct Mouse Genotyping Kit Plus: Mechanistic QC

  2026-09-08

  The Direct Mouse Genotyping Kit Plus can strengthen the genotype-to-phenotype audit trail in macrophage EP4 mouse models. This article connects rapid DNA preparation and high-fidelity PCR with assay decisions for transgene detection, gene knockout validation, and cardiovascular research reproducibility.

• Pexidartinib and the CSF1R Logic of Cell State

  2026-09-08

  Pexidartinib (PLX3397) offers a receptor-directed way to interrogate macrophage and microglial biology. This thought-leadership analysis connects CSF1R-mediated signaling inhibition in oncology with emerging evidence that microglial activation reshapes hippocampal synaptic balance, while defining the experimental safeguards needed for responsible translational interpretation.

• Calcitriol and NFIA: A New Lens on Bone Homeostasis

  2026-09-07

  A translational framework linking Calcitriol biology with NFIA-regulated bone remodeling, immune signaling, experimental design, and program strategy.

• HDAC Inhibitors Repress NUT Carcinoma Programs

  2026-09-07

  Shiota and colleagues developed a dCas9-based GFP reporter screen to identify compounds that suppress NUT-driven transcription, uncovering structurally diverse HDAC inhibitors as potent repressors of the NUT carcinoma program. Panobinostat and IRBM6 reduced megadomain-associated oncogenic transcription, promoted differentiation, and constrained tumor growth, providing a mechanistic rationale for combining chromatin-directed therapies.

• TNF-alpha Recombinant Murine Protein Workflow

  2026-09-05

  Build reproducible apoptosis and inflammation assays with a defined, trimeric murine cytokine rather than relying on poorly characterized conditioned media. This workflow uses TNF-alpha as a receptor-initiated benchmark alongside RNA Pol II degradation studies, helping separate inflammatory signaling from transcription-independent cell death.

• Luminescent ATP Cell Viability Assay Kit I

  2026-09-04

  This scenario-based guide explains how Luminescent ATP Cell Viability Assay Kit I (SKU K2041) supports sensitive cell viability measurement, cytotoxicity testing, and proliferation studies. It covers assay principles, experimental design, protocol parameters, interpretation limits, and practical vendor-selection considerations for reproducible laboratory workflows.

• Hoe 140: Potent Bradykinin Antagonism In Vitro

  2026-09-04

  Hock and colleagues characterized Hoe 140 as a structurally distinctive, highly potent bradykinin antagonist using receptor-binding, isolated-organ, and endothelial-cell assays. The study established a major potency advance over an earlier peptide antagonist while also showing inhibition of bradykinin-dependent vascular signaling, providing a foundation for later bradykinin-pathway pharmacology.

8006 records 1/534 page Next 12345 下5页 Last page